Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction

Thorax

Volumn 58, Issue 1, 2003, Pages 43-46

  Suissa, S ^a   Assimes, T ^a   Ernst, P ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS;

EID: 0037257432     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.1.43     Document Type: Article

References (10)

1. 2-adrenoceptor agonists. Eur J Clin Pharmacol 1989;36:415-7.
2. Kiely DG, Cargill RI, Grove A, et al. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax 1995;50:1062-6.
3. Maesen FPV, Costongs R, Smeets JJ, et al. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991;99:1367-73.
4. Lipworth BJ. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf 1992;7:54-70.
5. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598-602.
6. Au DH, Lemaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161:827-30.
7. Hole DJ, Watt GCM, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-5.
8. Downey W, Beck P, McNutt M, et al. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York: John Wiley & Sons, 2000: 325-46.
9. Suissa S. Novel approaches to pharmacoepidemiological study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York: John Wiley & Sons, 2000;785-805.
10. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.